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Objective. Primary Sjögren’s syndrome (SS) is a
systemic autoimmune disease with incompletely under-
stood etiology. This study was undertaken to investigate
the role of epigenetic dysregulation in the pathogenesis
of primary SS.
Methods. A genome-wide DNA methylation study
was performed in naive CD4 T cells from 11 patients
with primary SS compared to age-, sex-, and ethnicity-
matched healthy controls. Cytosine methylation was quan-
tified using the Illumina Infinium HumanMethylation
450 BeadChip array, and the data were validated using
bisulfite sequencing.
Results. Genome-wide analyses identified 553 hy-
pomethylated CpG sites and 200 hypermethylated CpG
sites in naive CD4 T cells from patients with primary
SS as compared to healthy controls, representing 311
hypomethylated and 115 hypermethylated gene regions.
The hypomethylated genes in patients with primary SS
included LTA (encoding lymphotoxin ). Other relevant
genes, such as CD247, TNFRSF25, PTPRC, GSTM1, and
PDCD1, were also hypomethylated. The interferon sig-
nature pathway was represented by hypomethylation of
STAT1, IFI44L, USP18, and IFITM1. A group of genes
encoding members of the solute carrier proteins were
differentially methylated. In addition, the transcription
factor gene RUNX1 was hypermethylated in patients
with primary SS, suggesting a possible connection to
lymphoma predisposition. Gene ontology (GO) analysis
of hypomethylated genes demonstrated enrichment of
genes involved in lymphocyte activation and immune
response. GO terms for hypermethylated genes included
antigen processing and presentation.
Conclusion. This is the first epigenome-wide DNA
methylation study in patients with primary SS. These
findings highlight a role for DNA methylation in pri-
mary SS and identify disease-associated DNA methyl-
ation changes in several genes and pathways in naive
CD4 T cells from patients with primary SS that may
be involved in the pathogenesis of this disease.
Primary Sjögren’s syndrome (SS) is a complex
autoimmune disease characterized by production of
autoantibodies against RNP particles (Ro/SSA and La/
SSB) and muscarinic acetylcholine receptor antigens,
dysfunction of water transport processes, and lympho-
cytic infiltration of exocrine glands resulting in glandular
atrophy and dysfunction (1,2). Although xerostomia
(dry mouth) and xerophthalmia (dry eyes) are the main
clinical features of primary SS (3), the full spectrum of
the disease encompasses involvement of different organ
systems and predisposition to lymphoproliferative dis-
ease (4). Primary SS predominantly affects women, with
a female-to-male distribution of 9 to 1 (5).
The etiology of primary SS is incompletely un-
derstood, but a growing body of evidence suggests that
diseases with certain clinical features similar to those of
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primary SS, such as systemic lupus erythematosus
(SLE), have common epigenetic factors that may con-
tribute to the pathogenesis of autoimmunity (6). Fur-
thermore, recent evidence suggests that global DNA
methylation is reduced in salivary gland epithelial cells
from patients with primary SS (7). DNA methylation is
considered the core epigenetic mechanism that regulates
gene expression, by altering transcriptional accessibility
of regulatory regions within gene sequences (8). In a
recent study, we characterized the DNA methylation
changes in naive CD4 T cells from patients with lupus,
revealing that changes in DNA methylation occurred
prior to the differentiation and activation of T cells, and
demonstrating that interferon (IFN)–regulated genes in
naive CD4 T cells from patients with lupus are epige-
netically poised for transcription (9). In the present
study, we performed a genome-wide DNA methylation
study in naive CD4 T cells from patients with primary
SS and healthy control subjects. We also validated our
results using bisulfite sequencing of selected differen-
tially methylated loci. The findings demonstrated a
pattern of differential methylation in key genes and
disease-associated pathways pertinent to the pathogen-
esis of primary SS.
PATIENTS AND METHODS
Patients and controls. We studied 11 patients with pri-
mary SS and 11 healthy control subjects. Patients and controls
were matched for age (within 5 years), sex, and ethnicity. The
demographic features and medications of the study partici-
pants are shown in Table 1. Classification of primary SS was
based on the American-European Consensus Group 2002
revised criteria (10). The clinical features of the patients with
primary SS included in this study are shown in Table 2. Disease
manifestations in the patients were extensively characterized
by a team of oral, ocular, and rheumatology specialists through
the Oklahoma Medical Research Foundation (OMRF)
Sjögren’s Research Clinic. Controls were recruited at the
OMRF and the University of Michigan. The institutional re-
view boards at the OMRF and the University of Michigan
approved this study. All study participants signed a written
informed consent form prior to participation.
Isolation and purity of naive CD4 T cells. Peripheral
blood mononuclear cells (PBMCs) were isolated from fresh
blood samples obtained from patients and controls using
density-gradient centrifugation (Ficoll-Paque; GE Healthcare
Life Sciences). Naive CD4 T cells were separated from
PBMCs using a naive CD4 T Cell Isolation Kit II (Miltenyi
Biotec) that allows for indirect isolation of naive CD4 T cells,
or by sorting the CD3CD4CD45RA naive T cell popu-
lation on a FACSAria instrument (BD Biosciences). The
purity of the naive CD4 T cells was confirmed by flow
cytometry, using fluorochrome-conjugated antibodies against
CD4 and CD45RA. The purity of the isolated naive CD4 T
cells was consistently 95%, regardless of the method used.
DNA was isolated using the DNeasy kit (Qiagen), as described
in the manufacturer’s protocol.
DNA methylation studies and array validation.
Genome-wide DNA methylation in naive CD4 T cells from
the patients with primary SS and healthy controls included in
this study was assessed using the Illumina Infinium Human-
Methylation450 BeadChip array, which allows for the interro-
gation of485,000 methylation sites within the entire genome.
This array covers 99% of RefSeq genes, with an average of 17
CpG sites per gene across the promoter region, 5-untranslated
region (5-UTR), first exon, gene body, and 3-UTR. It also
covers 96% of CpG islands. Non-CpG methylated sites re-
cently identified in human stem cells are also covered, as well
as microRNA promoter regions.
Validation of the array data was performed using bisulfite
DNA sequencing in selected hypermethylated and hypomethy-
lated gene regions. The primers were as follows: for HDAC4,
forward 5-TGGTTTTATTTTTTGTAGTTAAAAA-3 and
reverse 5-ATAAAACCTCTATACCTCACTCAAC-3; for
SLC38A4, forward 5-TTTGGATTTTTTAATTAAGTTGT-
TA-3 and reverse 5-TCTACAATATTAATACTCCTACAA-
ACC-3; for DUSP22, forward 5-TTATTTGTTTTTTTAGG-
GTAGGGAG-3 and reverse 5-AATCTCCAAATCCCCCT-
TTAAC-3; for GSTM1, forward 5-GTTAGGATTTGG-
TTGGTGTTTTAAG-3 and reverse 5-ATCCCAATACCC-
CAATATCATAAAC-3; for RUFY1, forward 5-GTAGG-
AGAGGTTTTGAGTTGGATT-3 and reverse 5-TCCTC-
CATCATCTAACACTTAAAAA-3; for NAPRT1, forward
Table 1. Demographic characteristics and medication use of the
study participants*
Subject/age/sex Ethnicity Medication
Patients with primary SS
1/50/female European American Methotrexate
2/51/female European American Hydroxychloroquine
3/30/female European American
4/23/female European American Hydroxychloroquine
5/62/female European American Azathioprine
6/32/female European American
7/35/female European American
8/60/female European American
9/58/female European American
10/35/female European American Hydroxychloroquine
11/69/female European American Hydroxychloroquine
Healthy controls
12/52/female European American
13/47/female European American
14/34/female European American
15/23/female European American
16/58/female European American
17/36/female European American
18/36/female European American
19/55/female European American
20/58/female European American
21/38/female European American
22/64/female European American
* The mean age of the patients with primary Sjögren’s syndrome (SS)
and healthy controls was 45.9 years and 45.5 years, respectively (P 
0.95).
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5-TATGGTGGTTTGGTAGAGGTTAGTG-3 and reverse
5-ACTAATCTATCCTCCACCCTTTCC-3; and for
SLC9A1, forward 5-GTTTTTTTATTTAGAGAGGGGTA-
GG-3 and reverse 5-AACCAAAAAAAACTACAACTAA-
ACC-3. We used a Bio-Rad T100 Thermocycler with the
following protocol: 1 cycle at 94°C for 5 minutes, followed by
40 cycles (94°C for 45 seconds, annealing temperature for each
primer set for 45 seconds, 72°C for 90 seconds), and then 74°C
for 10 minutes. The annealing temperatures for HDAC4,
SLC38A, DUSP22, GSTM1, RUFY1, NAPRT1, and SLC9A1
were 54°C, 57°C, 53°C, 54°C, 56°C, 56°C, and 53°C, respec-
tively.
We confirmed the presence of polymerase chain re-
action (PCR) product with the use of 1.6% agarose gel elec-
trophoresis. DNA was purified using a QIAquick PCR Purifi-
cation Kit (Qiagen), as specified by the manufacturer.
Bisulfite-treated DNA was sequenced using Sanger sequenc-
ing. The DNA methylation level on each CpG following bi-
sulfite sequencing was quantified using the Epigenomics
ESME software package.
Statistical and bioinformatics analyses. DNA methyl-
ation studies were performed using the GenomeStudio methyl-
ation analysis package (Illumina), as previously described (8).
The average level of DNA methylation ( value) on each CpG
site was compared between patients with primary SS and
healthy controls. To identify differentially methylated CpG
sites between patients and controls, we used 3 data-filtering
criteria: 1) CpG site with a mean difference in the DNA
methylation level of at least 1.2-fold, 2) differential methyl-
ation score of 22 (P  0.01), after adjustment for multiple
testing using a false discovery rate (FDR) of 5%, and 3) ex-
clusion of CpG sites assessed by probes with a genetic variant
located within 10 bp of the 3 end of the probe.
To systematically highlight the most overrepresented
biologic terms among the differentially methylated genes, we
performed gene ontology (GO), network, and pathway analy-
ses using the DAVID bioinformatics database (version 6.7)
(11). In pathway and GO analyses, we used an Expression
Analysis Systematic Explorer (EASE) score threshold of 0.1
for detection of gene enrichment. The EASE score represents
a modified P value determined by Fisher’s exact test, which is
considered to represent the significance of gene-term enrich-
ment. In addition, we used a fold enrichment threshold of 1.5,
with an FDR of 10% to correct for multiple testing (12).
RESULTS
We evaluated DNA methylation changes in naive
CD4 T cells from patients with primary SS and age-,
sex-, and ethnicity-matched healthy controls. We identi-
fied 753 differentially methylated CpG sites in naive
CD4 T cells from patients with primary SS (Table 3
and Supplementary Table 1, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.38264/abstract). Two hundred sites were
hypermethylated and 553 were hypomethylated in pa-
tients with primary SS as compared to healthy controls.
A total of 426 differentially methylated unique genes
were identified in naive CD4 T cells from patients with
primary SS, with the majority of the genes (311 [75%])
being hypomethylated. Bisulfite DNA sequencing was
used to validate the DNA methylation array results by
studying a group of hypermethylated (4 genes, 7 loci)
and hypomethylated (3 genes, 3 loci) CpG sites. The
mean Pearson’s correlation coefficient (r2 value) for the
correlation between the Illumina Infinium Human-
Methylation450 array data and the bisulfite sequencing
data was 0.803 (see Supplementary Figure 1, available
on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.38264/abstract).
Although the purity of the naive CD4 T cells
was consistently 95%, we wanted to ensure that the
differential methylation patterns identified between pa-
tients and controls in our study were not influenced
by potential differences in the naive CD4 T cell
activation status, which could have been induced by the
different isolation procedures used. We therefore exam-
ined the DNA methylation levels of a region in the IL2
promoter–enhancer sequence that is known to readily
demethylate upon T cell activation. Demethylation of
Table 2. Clinical characteristics of the patients with primary SS
(n  11)*
Dry eyes, no. (%) 11 (100)
Dry mouth, no. (%) 11 (100)
Schirmer’s test for eye dryness
Abnormal findings, no. (%) 6 (55)
Mean response, mm 10.8
Abnormal lissamine green ocular staining score, no. (%) 9 (82)
Abnormal WUSF, no. (%) 5 (45)
Positive for anti-Ro/SSA, no. (%) 6 (55)
Positive for anti-La/SSB, no. (%) 6 (55)
MSG biopsy findings consistent with primary SS, no. (%) 10 (91)
Mean focus score 4.5
* The focus score is the number of mononuclear cell infiltrates
containing at least 50 inflammatory cells in a 4-mm2 glandular section.
SS  Sjögren’s syndrome; WUSF  whole unstimulated salivary flow;
MSG  minor salivary gland.
Table 3. Summary of the differentially methylated CpG sites and
genes in naive CD4 T cells from patients with primary Sjögren’s
syndrome as compared to healthy controls
Increased
methylation
Decreased
methylation Total
No. of CpG sites 200 553 753
Fold change
Range 1.20, 5.20 1.20, 5.22
Mean 1.65 1.60
Differential score
Range 22.0, 342.0 22.0, 339.8
Mean 95.6 66.1
No. of genes 115 311 426
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the promoter–enhancer region of IL2 is a sensitive
indicator of CD4 T cell activation (13,14) and is a
prerequisite for IL2 transcription (15). We detected high
DNA methylation levels in the IL2 promoter–enhancer
region, as expected in naive CD4 T cells, and there was
no difference between patients and controls (see Sup-
plementary Table 2, available on the Arthritis & Rheu-
matology web site at http://onlinelibrary.wiley.com/doi/
10.1002/art.38264/abstract).
Furthermore, we examined the DNA methylation
levels in genetic loci known to demethylate in specific
antigen–experienced and regulatory CD4 T cell sub-
sets, including IFNG (Th1 cells), IL4, IL5, and IL13
(Th2 cells), IL17 (IL17A) and IL17F (Th17 cells), and
FOXP3 (regulatory T cells). Again, we observed that the
DNA methylation levels were consistently high across
these genetic loci, and there was no difference between
patients and controls (see Supplementary Table 2, avail-
able on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.38264/abstract).
The hypomethylated genes detected in naive
CD4 T cells from patients with primary SS included
LTA (encoding lymphotoxin  [LT]), which is involved
in the LT receptor (LTR) signaling pathway, activa-
tion of follicular dendritic cells, and expression of IFN.
We identified 5 differentially methylated CpG sites in
LTA, located at the 5-UTR within 200 bp upstream of
the transcriptional start site (hereafter referred to as
TSS 200) and in the first exon (Figure 1). The mean
differential methylation score (Diff. score) of the 5 CpG
sites was 35.4 (range 22.3 to 53.8; mean fold
change 1.82). Other relevant hypomethylated genes in-
cluded CD247, which encodes for T cell receptor (TCR)
-chain (2 CpG sites located in the body of the gene,
with Diff. scores of 23.9 and 32.3, respectively; mean
fold change 1.96), TNFRSF25 (1 CpG site located 1,500
bp upstream of the TSS [TSS 1,500], with a Diff. score of
23.2; mean fold change 1.59), PTPRC (2 CpG sites in
the body of the gene and in TSS 1,500, with Diff. scores
of 49.7 and 75.5, respectively; mean fold change
1.96), GSTM1 (2 CpG sites located in TSS 200, with Diff.
scores of 31.4 and 48.8, respectively; mean fold
change 1.40), and PDCD1 (1 CpG site located in TSS
1,500, with a Diff. score of 46.9; mean fold change
2.63). The type I IFN pathway, which plays a major role
in the pathogenesis of primary SS (16), was represented
by hypomethylation of STAT1 (2 CpG sites located in
the 5-UTR, with Diff. scores of 23.9 and 79.2,
respectively; mean fold change 1.41), IFI44L (1 CpG site
located in the 5-UTR, with a Diff. score of24.1; mean
fold change 1.22), IFITM1 (1 CpG site located in TSS
1,500, with a Diff. score of 35.8; mean fold change
1.75), and USP18 (1 CpG site located in the 5-UTR,
with a Diff. score of 65.1; mean fold change 1.40).
Figure 1. DNA methylation of the LTA gene (encoding lymphotoxin ) in naive CD4 T cells from patients with primary Sjögren’s syndrome and
healthy controls. A, Schematic of LTA DNA methylation (31,539,814–31,542,537 bp on chromosome 6; GRCh37/hg19), depicting the location of the
CpG sites evaluated. UTR  untranslated region. B, DNA methylation fractions ( values) across the CpG sites in LTA, evaluated in naive CD4
T cells from patients with primary Sjögren’s syndrome and healthy controls. Asterisks indicate the 5 hypomethylated CpG sites in the LTA gene
region in cases compared to controls. Values are the mean  SD.
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Table 4. Pathway analysis of the differentially methylated genes in naive CD4 T cells from patients with primary Sjögren’s syndrome as compared
to healthy controls*
Category Term Molecule P
Fold
enrichment FDR
KEGG_PATHWAY Type 1 diabetes mellitus PTPRN2; CD28; LTA; HLA–A; HLA–B;
HLA–C; HLA–F; HLA–DMA; HLA–DRB1;
HLA–DRB4; HLA–DRB5
4.59  106 9.005 0.005
KEGG_PATHWAY Allograft rejection CD28; HLA–A; HLA–B; HLA–C; HLA–F;
HLA–DMA; HLA–DRB1; HLA–DRB4;
HLA–DRB5
1.66  104 8.171 0.191
KEGG_PATHWAY Viral myocarditis MYH13; CD28; CASP9; HLA–A; HLA–B;
HLA–C; HLA–F; HLA–DMA; HLA–DRB1;
HLA–DRB4; HLA–DRB5
2.34  104 5.327 0.268
KEGG_PATHWAY Graft-versus-host disease CD28; HLA–A; HLA–B; HLA–C; HLA–F;
HLA–DMA; HLA–DRB1; HLA–DRB4;
HLA–DRB5
2.63  104 7.543 0.301
KEGG_PATHWAY Autoimmune thyroid disease CD28; HLA–A; HLA–B; HLA–C; HLA–F;
HLA–DMA; HLA–DRB1; HLA–DRB4;
HLA–DRB5
1.15  103 5.768 1.315
KEGG_PATHWAY Antigen processing and presentation LTA; HLA–A; HLA–B; HLA–C; HLA–F;
HLA–DMA; HLA–DRB1; HLA–DRB4;
HLA–DRB5; TAP2
3.22  103 4.051 3.637
KEGG_PATHWAY Cell adhesion molecules NCAM1; SELL; PDCD1; CD28; HLA–A;
HLA–B; HLA–C; HLA–F; HLA–DMA;
HLA–DRB1; HLA–DRB4; HLA–DRB5
3.73  103 3.184 4.201
* FDR  false discovery rate; KEGG  Kyoto Encyclopedia of Genes and Genomes.
Table 5. GO analysis of hypomethylated and hypermethylated genes in naive CD4 T cells from patients with primary Sjögren’s syndrome*
Category GO term
GO
identification
no. Gene P
Fold
enrichment FDR
Hypomethylated genes
GOTERM_BP_FAT Lymphocyte activation 0046649 BCL11B; CD3G; CD28; CD7; CHD7;
FOXP1; HDAC4; ITPKB; JMJD6;
RHOH; SLC11A1; SKAP2; UNC13D
1.10  104 3.859 0.185
GOTERM_BP_FAT Leukocyte differentiation 0002521 BCL11B; CEBPE; CD28; CHD7;
FOXP1; HDAC4; ITPKB; JMJD6;
RHOH
1.42  103 4.168 2.361
GOTERM_BP_FAT Immune response 0006955 BTLA; CD28; CD300A; CD7; FAIM3;
ST6GAL1; C4BPB; FOXP1; IFI44L;
IL36G; IL16; LY86; LTA; HLA–A;
HLA–B; HLA–H; HLA–DRB5;
PDCD1; SLC11A1; TCF12; TCF7;
UNC13D; ETS1
2.20  103 1.969 3.646
GOTERM_BP_FAT Chromatin organization 0006325 BCOR; CREBBP; DNMT3A; H2AFV;
SATB1; SMARCB1; APBB1; CHD7;
HDAC4; JMJD6; KDM2B; RBBP7;
TSPY4; TSPY1; TSPY2; TSPY3;
TSPY7P; TLK1
3.90  103 2.344 6.356
GOTERM_BP_FAT T cell differentiation 0030217 BCL11B; CD28; CHD7; ITPKB;
JMJD6; RHOH
4.20  103 5.453 6.855
GOTERM_BP_FAT Homophilic cell adhesion 0007156 PCDHAC2; PCDHA2; PCDHA3;
PCDHA4; PCDHA5; PCDHA7;
PCDHA8; PCDHA9
5.80  103 3.608 9.360
GOTERM_BP_FAT L-amino acid transport 0015807 CACNA1A; HTT; SLC11A1; SLC7A8 6.10 103 10.274 9.687
Hypermethylated genes
GOTERM_BP_FAT Antigen processing and
presentation
0019882 TAP2; HLA–B; HLA–C; HLA–F;
HLA–H; HLA–DMA; HLA–DRB4;
HLA–DRB5
6.89  106 14.817 0.010
* Statistically significant gene ontology (GO) terms are shown. FDR  false discovery rate; GOTERM_BP_FAT  gene ontology term biologic process.
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A group of genes encoding members of the solute
carrier proteins, which are membrane transport proteins
that are important for maintenance of cell function,
were hypomethylated, including SLC11A1, SLC11A2,
SLC22A23, SLC25A25, SLC25A3, SLC25A33, and
SLC6A20, whereas SLC9A1, which is important for the
maintenance of pH homeostasis, was hypermethylated
in patients with primary SS as compared to healthy
controls. In addition, the transcription factor RUNX1
was hypermethylated in patients with primary SS. Sup-
plementary Table 1 (available on the Arthritis & Rheu-
matology web site at http://onlinelibrary.wiley.com/doi/
10.1002/art.38264/abstract) provides a summary of all
CpG sites that were differentially methylated in patients
with primary SS in our study.
Next, we used DAVID software (11) to facilitate
the systematic identification and grouping of differen-
tially methylated genes into biologic networks. Canoni-
cal pathway analysis identified type 1 diabetes mellitus
(P 4.59 106), allograft rejection (P 1.66 104),
viral myocarditis (P  2.34  104), graft-versus-host
disease (P  2.63  104), autoimmune thyroid disease
(P  1.15  103), antigen processing and presentation
(P  3.22  103), and cell adhesion molecules (P 
3.73  103) as the most significant pathways unifying
the differentially methylated genes in naive CD4 T
cells from patients with primary SS (Table 4).
GO analysis of hypomethylated genes demon-
strated enrichment of genes involved in lymphocyte
activation (P  1.10  104), leukocyte differentiation
(P 1.42 103), immune response (P 2.20 103),
chromatin organization (P  3.90  103), T cell
differentiation (P  4.20  103), homophilic cell
adhesion (P 5.80 103), and L-amino acid transport
(P 6.10 103). GO terms for hypermethylated genes
included antigen processing and presentation ontology
(P  6.89  106) (Table 5).
DISCUSSION
In this study, we performed an unbiased genome-
wide DNA methylation analysis of naive CD4 T cells
from patients with primary SS, and thereby identified a
set of differentially methylated genes and involved path-
ways in patients with primary SS as compared to
matched healthy controls. The molecular basis of pri-
mary SS is not well characterized; however, cumulative
evidence indicates that activation of the LTR pathway
plays an integral role in the pathogenesis of primary SS
(17). We identified 5 hypomethylated CpG sites in the
LTA gene in naive CD4 T cells from patients with
primary SS as compared to healthy controls.
Lymphotoxins (LT, LT) and their receptors
are part of the tumor necrosis factor superfamily (18).
Soluble LT promotes production of IFNs and multiple
chemokines that are important activating signals to the
immune cells (19). Moreover, LT forms a heterodimer
with LT (LT12), which in turn binds to LTR (20).
Activation of the LTR pathway is crucial for the de-
velopment, organization, and maintenance of lymphoid
structures (21) and for modulating the expression of
chemokines and adhesion molecules that aid in traf-
ficking of lymphocytes and follicular dendritic cell acti-
vation (22).
Furthermore, studies in murine models have
highlighted an interesting role of LT in the pathogen-
esis of Sjögren’s-like disease. LT was found to be
overexpressed in the salivary gland secretions and sera
of IL14-transgenic (TG) mice, a murine model of SS
(23). The IL14-TG mouse reproduces the clinical and
immunologic changes characteristic of SS (24). Interest-
ingly, IL14-TG mice with deletion of the LTA gene did
not develop disease (23). In another murine model of SS
using NOD mice, Gatumu and colleagues (22) showed
that blocking the LTR pathway resulted in ablation of
the lymphoid organization in the NOD mouse salivary
glands and an improvement in salivary gland function
(22). In another study, blocking of LTR reduced the
size of leukocyte infiltrates in the lacrimal glands, and
improved tear production and corneal integrity (25).
Additional evidence that LT has a role in SS comes
from the observation that LT is overexpressed in the
salivary glands and sera of patients with SS (23). Indeed,
a clinical trial to evaluate the use of an LTR fusion
protein (baminercept) in the treatment of patients with
primary SS is currently in progress. Our results suggest
that epigenetic factors may play a role in LT over-
expression in patients with primary SS, as cytosine
demethylation predisposes patients to transcriptionally
permissive chromatin architecture in this locus.
Patients with primary SS have an activated type I
IFN response (16,26), as has been demonstrated by ob-
servations of increased type I IFN activity and an “IFN
signature” in PBMCs (27), saliva (28), and minor sali-
vary gland biopsy tissue (29,30) from patients with
primary SS. Several of the hypomethylated genes that
were identified herein in naive CD4 T cells from
patients with primary SS were IFN-regulated genes
(STAT1, IFI44L, IFITM1, and USP18). The extent of
hypomethylation of IFN-regulated genes seems to be
less robust in patients with primary SS in comparison to
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patients with SLE (9), in whom we have recently iden-
tified and reproduced 21 hypomethylated IFN-regulated
genes in naive CD4 T cells.
In this study, we identified several differentially
methylated genes that are important in activation of the
immune system. CD247 encodes for the TCR -chain, is
important for signal transduction upon antigen stimula-
tion (31), and was hypomethylated in naive CD4 T
cells in patients with primary SS. Other pertinent genes
included PTPRC, which encodes protein tyrosine phos-
phatase, receptor type C (also known as CD45 antigen
or B220). PTPRC is a signaling molecule that is essential
for T and B cell activation, cellular differentiation, and
oncogenic transformation (32). TNFRSF25, which plays
a role in lymphocyte homeostasis and in apoptosis, was
also hypomethylated in patients with primary SS. Fur-
thermore, we detected hypomethylation of GSTM1,
which encodes a cytoplasmic glutathione S-transferase
that is important in detoxification of electrophilic com-
pounds, including carcinogens and environmental toxins
(33). Of particular interest, GSTM1 was proposed as a
genetic risk locus for primary SS in a previous study (34),
which might suggest that this gene has a role in genetic–
epigenetic interactions in the pathogenesis of primary
SS. Indeed, we have previously demonstrated a genetic
association between primary SS and variants in MECP2
(encoding methyl-CpG binding protein 2), a key tran-
scriptional regulator with a critical role in DNA methyl-
ation (35). Among the transcription factors, we identi-
fied RUNX1 as a hypermethylated gene in the present
study. RUNX-1 regulates the differentiation of hemato-
poietic stem cells into mature cells (36) and has been
linked to cancer predisposition (37,38). These findings
suggest that RUNX1 has a possible connection to lym-
phoma predisposition in primary SS.
It is generally accepted that defects in mem-
brane water channel proteins contribute to the exocri-
nopathy in patients with primary SS (39). Our study
identified several differentially methylated genes encod-
ing members of the solute carrier proteins. The genes
SLC11A1, SLC11A2, SLC22A23, SLC25A25, SLC25A3,
SLC25A33, and SLC6A20 were hypomethylated, whereas
SLC9A1, which is expressed in the kidneys and plays an
important role in the maintenance of pH homeostasis,
was hypermethylated in patients with primary SS as
compared to healthy controls. Mutations in solute car-
rier proteins have been previously linked to diseases
associated with acid-base disturbances, such as Bartter
and Gitelman syndromes (40). We hypothesize that
methylation changes in these proteins may explain some
of the pathologic aspects of primary SS–like defects in
molecular water transport, dysfunction of the exocrine
glands, and perhaps distal renal tubular acidosis in some
patients with primary SS (41).
We used the DAVID database to facilitate the
systematic identification and grouping of differentially
methylated genes into biologic networks. Of particular
interest, there was enrichment of ontologies involved in
both the adaptive and the innate immune systems,
underscoring involvement of the 2 arms of immunity in
the pathogenesis of primary SS (Table 5).
Two cell-separation methods were used to isolate
naive CD4 T cells from patients and controls, albeit
with consistent and equal cell purity (95%). We fur-
ther confirmed the absence of T cell activation or
differentiation in the study samples with the use of
epigenetic immunophenotyping, in which we examined
the methylation status of IL2, IFNG, IL4, IL5, IL13,
IL17, IL17F, and FOXP3. It is important to note that
identification of the phenotypic specificity of cells is
critical to accurately and reliably interpret differential
methylation data in autoimmune diseases, while avoid-
ing any perceived differences that could be related to
altered cell constituents.
DNA methylation is tightly linked to chromatin
accessibility, and gene expression requires both chroma-
tin accessibility and appropriate transcription factors.
Therefore, some, but not all, of the differences in DNA
methylation identified in the present study can be ex-
pected to be associated with expression differences.
Examining DNA methylation at a genome-wide level
provides another level for discovering fundamental dif-
ferences that might be pathogenic in the disease process
at the chromatin level, which might or might not be
linked directly to expression differences. For example,
we recently observed that naive CD4 T cells from
lupus patients had widespread hypomethylation of IFN-
regulated genes, before an expression difference could
be detected (9). Interestingly, to our knowledge, there
has not yet been a gene expression study of naive CD4
T cells from patients with primary SS, and therefore we
do not know which genes are differentially expressed in
naive CD4 T cells in this disease. Therefore, whether
some of the methylation changes detected in this first
DNA methylation study in patients with primary SS are
reflective of a difference in the active (or potential) gene
expression state remains to be seen.
The recent advances in epigenetics and the emer-
gence of epigenome-wide association studies have re-
sulted in the successful identification of numerous in-
triguing associations between epigenomic perturbations
and human disease. However, this field is still in its
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infancy and the issue of “causality” related to the
detected epigenetic changes will require careful experi-
mental examination. The issue of causality inference is
even more complicated in patients with primary SS, for
several reasons. First, understanding of the genetic
predisposition to primary SS, which might influence
epigenetic variations, is incomplete. Second, the envi-
ronmental factors involved in the pathogenesis of pri-
mary SS remain, by and large, uncharacterized. Third,
our study was designed as a retrospective case–control
study; alternative study designs would be longitudinal
studies of monozygotic twins discordant for primary SS
or prospective studies to evaluate epigenetic perturba-
tions prior to the onset of the disease, both of which are
study designs that are cumbersome for obvious reasons.
Nevertheless, such studies are warranted in the future to
move this field forward (42).
Integrating emerging genomic data from patients
with primary SS with epigenomic profiling might provide
an avenue to discover mechanistic and pathogenic path-
ways to this disease. For example, we suspect that some
genetic susceptibility variants that will be discovered in
patients with primary SS might influence some of the
methylation differences observed. A simultaneous
genomic–epigenomic analysis should therefore focus on
allele-specific methylation changes induced by genetic
variants associated with primary SS. These approaches
will help to identify novel mechanisms and therapeutic
targets for this disease, and might enhance our under-
standing of the functional consequences of some of the
genetic susceptibility loci in primary SS.
In summary, we identified, for the first time,
DNA methylation changes in naive CD4 T cells from
patients with primary SS. These data indicate that
abnormal DNA methylation exists in CD4 T cells,
even before the activation and differentiation of T cells,
in patients with primary SS. Therefore, our findings
emphasize the potential role of DNA methylation
changes in the pathogenesis of primary SS. Our study
demonstrates differential methylation of LTA, type I
IFN–regulated genes, and solute carrier proteins, in
addition to other key genes and pathways involved in the
pathogenesis of primary SS. Future studies to replicate
anddetermine the functional consequencesof themethyl-
ation changes observed upon pathophysiologic develop-
ment of the disease are warranted.
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